May 19 - Genfit sa GNFT.PA :
* REPORTED ON MONDAY Q1 REVENUES EUR 102,000 VS EUR 1,000 YR
AGO
* END-MARCH CASH AND CASH EQUIVALENTS EUR 252.0 MLN VS
EUR
314.1 MLN YR AGO
* TO SHARE UPDATED CORPORATE STRATEGY IN AUTUMN 2020, ONCE
DECISION ON RESOLVE-IT TRIAL IS TAKEN
* REMAINS FULLY COMMITTED TO DEVELOPING NIS4™
* REGARDING PBC, GENFIT IS CONFIDENT IN PHASE 3 PROGRAM
EVALUATING
ELAFIBRANOR IN INDICATION
Source text for Eikon: urn:newsml:reuters.com:*:nGNE8FtKX7
Further company coverage: GNFT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 7785110))